Literature DB >> 25879865

Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease.

Anja Soldan1, Corinne Pettigrew1, Yi Lu2, Mei-Cheng Wang2, Ola Selnes1, Marilyn Albert1, Timothy Brown3, J Tilak Ratnanather3, Laurent Younes4, Michael I Miller3.   

Abstract

This study evaluated the utility of baseline and longitudinal magnetic resonance imaging (MRI) measures of medial temporal lobe brain regions collected when participants were cognitively normal and largely in middle age (mean age 57 years) to predict the time to onset of clinical symptoms associated with mild cognitive impairment (MCI). Furthermore, we examined whether the relationship between MRI measures and clinical symptom onset was modified by apolipoprotein E (ApoE) genotype and level of cognitive reserve (CR). MRI scans and measures of CR were obtained at baseline from 245 participants who had been followed for up to 18 years (mean follow-up 11 years). A composite score based on reading, vocabulary, and years of education was used as an index of CR. Cox regression models showed that lower baseline volume of the right hippocampus and smaller baseline thickness of the right entorhinal cortex predicted the time to symptom onset independently of CR and ApoE-ɛ4 genotype, which also predicted the onset of symptoms. The atrophy rates of bilateral entorhinal cortex and amygdala volumes were also associated with time to symptom onset, independent of CR, ApoE genotype, and baseline volume. Only one measure, the left entorhinal cortex baseline volume, interacted with CR, such that smaller volumes predicted symptom onset only in individuals with lower CR. These results suggest that MRI measures of medial temporal atrophy, ApoE-ɛ4 genotype, and the protective effects of higher CR all predict the time to onset of symptoms associated with MCI in a largely independent, additive manner during the preclinical phase of Alzheimer's disease.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  amygdala; apolipoprotein E; education; entorhinal cortex; hippocampus; mild cognitive impairment; structural MRI

Mesh:

Substances:

Year:  2015        PMID: 25879865      PMCID: PMC4478167          DOI: 10.1002/hbm.22810

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  81 in total

1.  What provides cerebral reserve?

Authors:  Roger T Staff; Alison D Murray; Ian J Deary; Lawrence J Whalley
Journal:  Brain       Date:  2004-03-26       Impact factor: 13.501

2.  The relation between brain activity during memory tasks and years of education in young and older adults.

Authors:  Mellanie V Springer; Anthony R McIntosh; Gordon Winocur; Cheryl L Grady
Journal:  Neuropsychology       Date:  2005-03       Impact factor: 3.295

Review 3.  Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve.

Authors:  Daniel Barulli; Yaakov Stern
Journal:  Trends Cogn Sci       Date:  2013-09-07       Impact factor: 20.229

4.  Cognitive decline and literacy among ethnically diverse elders.

Authors:  Jennifer J Manly; Nicole Schupf; Ming-X Tang; Yaakov Stern
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-12       Impact factor: 2.680

5.  Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis.

Authors:  R Jenkins; N C Fox; A M Rossor; R J Harvey; M N Rossor
Journal:  Arch Neurol       Date:  2000-02

6.  Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype.

Authors:  Marilyn Albert; Anja Soldan; Rebecca Gottesman; Guy McKhann; Ned Sacktor; Leonie Farrington; Maura Grega; Raymond Turner; Yi Lu; Shanshan Li; Mei-Cheng Wang; Ola Selnes
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

Review 7.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

8.  Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network.

Authors:  Christopher A Hostage; Kingshuk Roy Choudhury; P Murali Doraiswamy; Jeffrey R Petrella
Journal:  Radiology       Date:  2013-12-12       Impact factor: 11.105

9.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Authors:  C R Jack; M M Shiung; J L Gunter; P C O'Brien; S D Weigand; D S Knopman; B F Boeve; R J Ivnik; G E Smith; R H Cha; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

10.  The diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease.

Authors:  Michael I Miller; Laurent Younes; J Tilak Ratnanather; Timothy Brown; Huong Trinh; Elizabeth Postell; David S Lee; Mei-Cheng Wang; Susumu Mori; Richard O'Brien; Marilyn Albert
Journal:  Neuroimage Clin       Date:  2013-09-16       Impact factor: 4.881

View more
  47 in total

Review 1.  Defining Cognitive Reserve and Implications for Cognitive Aging.

Authors:  Corinne Pettigrew; Anja Soldan
Journal:  Curr Neurol Neurosci Rep       Date:  2019-01-09       Impact factor: 5.081

2.  AD risk score for the early phases of disease based on unsupervised machine learning.

Authors:  Zheyu Wang; Zhuojun Tang; Yuxin Zhu; Corinne Pettigrew; Anja Soldan; Alden Gross; Marilyn Albert
Journal:  Alzheimers Dement       Date:  2020-07-30       Impact factor: 21.566

3.  Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway.

Authors:  V R Varma; S Varma; Y An; T J Hohman; S Seddighi; R Casanova; A Beri; E B Dammer; N T Seyfried; O Pletnikova; A Moghekar; M R Wilson; J J Lah; R J O'Brien; A I Levey; J C Troncoso; M S Albert; M Thambisetty
Journal:  Mol Psychiatry       Date:  2016-11-22       Impact factor: 15.992

4.  Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years.

Authors:  Marilyn Albert; Yuxin Zhu; Abhay Moghekar; Susumu Mori; Michael I Miller; Anja Soldan; Corinne Pettigrew; Ola Selnes; Shanshan Li; Mei-Cheng Wang
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

5.  Medial temporal lobe white matter pathway variability is associated with individual differences in episodic memory in cognitively normal older adults.

Authors:  Kylie H Alm; Andreia V Faria; Abhay Moghekar; Corinne Pettigrew; Anja Soldan; Susumu Mori; Marilyn Albert; Arnold Bakker
Journal:  Neurobiol Aging       Date:  2019-11-21       Impact factor: 4.673

6.  Cognitive reserve and rate of change in Alzheimer's and cerebrovascular disease biomarkers among cognitively normal individuals.

Authors:  Corinne Pettigrew; Anja Soldan; Yuxin Zhu; Qing Cai; Mei-Cheng Wang; Abhay Moghekar; Michael I Miller; Baljeet Singh; Oliver Martinez; Evan Fletcher; Charles DeCarli; Marilyn Albert
Journal:  Neurobiol Aging       Date:  2019-12-17       Impact factor: 4.673

7.  Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Authors:  Lei Cao; Hui-Fu Wang; Lin Tan; Fu-Rong Sun; Meng-Shan Tan; Chen-Chen Tan; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2016-03-22

8.  Performance on a 1-week delayed recall task is associated with medial temporal lobe structures in neurologically normal older adults.

Authors:  R Saloner; K B Casaletto; G Marx; S Dutt; A B Vanden Bussche; M You; E Fox; J Stiver; J H Kramer
Journal:  Clin Neuropsychol       Date:  2017-08-31       Impact factor: 3.535

9.  Cognitive reserve and cortical thickness in preclinical Alzheimer's disease.

Authors:  Corinne Pettigrew; Anja Soldan; Yuxin Zhu; Mei-Cheng Wang; Timothy Brown; Michael Miller; Marilyn Albert
Journal:  Brain Imaging Behav       Date:  2017-04       Impact factor: 3.978

Review 10.  Cognitive Reserve from the Perspective of Preclinical Alzheimer Disease: 2020 Update.

Authors:  Anja Soldan; Corinne Pettigrew; Marilyn Albert
Journal:  Clin Geriatr Med       Date:  2019-11-15       Impact factor: 3.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.